Skip to main content

Table 1 Efficacy results of major aromatase inhibitor trials

From: Update on the use of aromatase inhibitors in early-stage breast cancer

Trial AI versus tamoxifen Strategy Follow-up, months DFS HR DFS Pvalue OS HR OS Pvalue
ATAC Anastrozole Up-front 100 0.85 0.003 0.97 0.7
BIG Letrozole Up-front 76 0.88 0.03 0.87 0.8
BIG Letrozole-Tamoxifen Sequencing 71 0.96 NS   NS
BIG Tamoxifen-Letrozole Sequencing 71 1.05 NS   NS
TEAM Examestane Up-front 33 0.89 0.12   NS
IES Examestane Sequencing 55.7 0.76 0.0001   NS
ARNO Anastrozole Sequencing 30 0.66 0.049 0.53 0.045
MA-17 Letrozole Extended 30 0.58 0.001   NS
ABCSG 6a Anastrozole Extended 62 0.62 0.031   NS
  1. ABCSG, Austrian Breast & Colorectal Cancer Study Group; AI, aromatase inhibitor; ARNO, Arimidex-Nolvadex; ATAC, Arimidex, Tamoxifen, Alone or in Combination; BIG, Breast International Group; DFS, disease-free survival; HR, hazard ratio; IES, Intergroup Exemestane Study; NS, not significant; OS, overall survival; TEAM, Tamoxifen Exemestane Adjuvant Multinational.